{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:24:37Z","timestamp":1793381077428,"version":"4.5.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The study sought to delineate the cutaneous toxicity spectrum of immune-checkpoint inhibitors by using the US FDA Adverse Event Reporting System, and to qualify association with other immune-related adverse events (irAEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Disproportionality analyses relied on Reporting Odds Ratio (ROR), Bayesian Confidence Propagation Neural Network (BCPNN) and proportional reporting ratio (PRR). Univariable and multivariable logistic regression were then applied to identify other irAEs that predicted irAE-Cutaneous.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>(1) Most reports involved men aged &amp;gt;65\u00a0years. (2) Toxicity spectrum and outcomes: Most reports involved men over 65. Five drugs showed positive signals via the three algorithms. Immune-mediated dermatitis had the strongest signals across all. Ipilimumab strongly linked to vitiligo (ROR = 45.531); nivolumab (ROR = 9.656) and pembrolizumab (ROR = 8.376) to psoriasiform dermatitis; tislelizumab to acquired epidermolysis bullosa (ROR = 8.376). Rash and pruritus were common but weakly specific. Pembrolizumab had highest RORs for toxic epidermal necrolysis (ROR = 4.384) and Stevens-Johnson syndrome (ROR = 3.599). Nivolumab had most severe event reports, then pembrolizumab. (3) Association with other irAEs: Univariable analysis linked pneumonitis, hyperthyroidism, myositis, fatigue, hypothyroidism to skin irAEs (all P &amp;lt; 0.05); multivariable analysis found hyperthyroidism, myositis, fatigue, hypothyroidism as independent predictors (P &amp;lt; 0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Distinct toxicity spectra of each drug were observed. Hyperthyroidism, myositis, fatigue and hypothyroidism independently increase the likelihood of irAE-Cutaneous.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1684390","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T06:29:18Z","timestamp":1767335358000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Spectrum mining of immune checkpoint inhibitor-related cutaneous toxicities and analysis of associated factors based on FAERS"],"prefix":"10.3389","volume":"16","author":[{"given":"Siyao","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1177\/10781552221074623","article-title":"Cutaneous stevens johnson-toxic epidermal necrolysis immunotherapy related toxicities in lung cancer patients","volume":"28","author":"Alexandris","year":"2022","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B2","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1053\/j.seminoncol.2018.09.001","article-title":"Management of immunotherapy toxicities in older adults","volume":"45","author":"Bhandari","year":"2018","journal-title":"Seminars Oncology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15569527.2022.2034842","article-title":"Adverse cutaneous toxicities by PD-1\/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance","volume":"20","author":"Bhardwaj","year":"2022","journal-title":"Cutan. Ocul. Toxicol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/imr.13262","article-title":"Effects of immunerelated adverse events(irAEs)and their treatment on antitumor immune responses","volume":"318","author":"Blum","year":"2023","journal-title":"Immunol. Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1016\/j.bbi.2012.06.011","article-title":"Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications","volume":"30","author":"Bower","year":"2013","journal-title":"Brain Behav. Immun."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2147\/CMAR.S163391","article-title":"Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3390\/nu14030591","article-title":"The role of nutrition in immune-mediated, inflammatory skin disease: a narrative review","volume":"14","author":"Diotallevi","year":"2022","journal-title":"Nutrients"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/cncr.29918","article-title":"Beyond the dose-limiting toxicity period: dermatologic adverse events of patients on phase 1 trials of the cancer therapeutics evaluation program","volume":"122","author":"Drilon","year":"2016","journal-title":"Cancer"},{"key":"B9","volume-title":"Mining and analysis of adverse reaction signals of immune checkpoint inhibitors","author":"Fan","year":"2023"},{"key":"B10","unstructured":"FDA adverse event reporting System[EB\/OL]\n          \n          \n          2024"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy","volume":"22","author":"Goldinger","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"B13","first-page":"448","article-title":"The relationship between thyroid hormones, thyroid-stimulating hormone and skin","volume":"26","author":"He","year":"2020","journal-title":"Med. Rev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1016\/j.jtho.2021.06.019","article-title":"Updated overall survival analysis from IMpower110: atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1-Selected NSCLC","volume":"16","author":"Jassem","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1136\/annrheumdis-2018-214748","article-title":"Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists?","volume":"78","author":"Kostine","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.crphar.2022.100146","article-title":"Exploring genetic and immune underpinnings of the sexual dimorphism in tumor response to immune checkpoints inhibitors: a narrative review","volume":"4","author":"Mazzaschi","year":"2023","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"B18","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.alit.2022.01.001","article-title":"Immune-related adverse events in various organs caused by immune checkpoint inhibitors","volume":"71","author":"Okiyama","year":"2022","journal-title":"Allergol. Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The next decade of immune checkpoint therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1498215","DOI":"10.3389\/fphar.2024.1498215","article-title":"Safety assessment of deutetrabenazine: real-world adverse event analysis from the FAERS database","volume":"15","author":"Shu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.7547\/0980081","article-title":"An appraisal of potential drug interactions in cigarette smokers and alcohol drinkers","volume":"99","author":"Smith","year":"2009","journal-title":"J. Am. Podiatric Med. Assoc."},{"key":"B24","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/cup.12876","article-title":"Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy","volume":"44","author":"Vivar","year":"2017","journal-title":"J. Cutan. Pathol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1071983","DOI":"10.3389\/fimmu.2023.1071983","article-title":"Cutaneous manifestations associated with immune checkpoint inhibitors","volume":"14","author":"Watanabe","year":"2023","journal-title":"Front. Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (checkMate 037):a randomised,controlled,open-label,phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"LancetOncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1226086","DOI":"10.3389\/fphar.2023.1226086","article-title":"Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system","volume":"14","author":"Xiong","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1007\/s00432-022-04425-z","article-title":"Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1\/PD-L1 inhibitor monotherapy","volume":"149","author":"Yamaguchi","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B30","doi-asserted-by":"publisher","first-page":"350","DOI":"10.16761\/j.cnki.1000-4963.2018.06.005","article-title":"Study on the correlation between vitiligo and cellular immunity, autoimmune thyroid disease and sex hormone levels","volume":"47","author":"Zhou","year":"2018","journal-title":"J. Clin. Dermatology"},{"key":"B31","volume-title":"Analysis of the incidence, clinical characteristics and risk factors of rheumatic and immune-related adverse reactions caused by immune checkpoint inhibitors [D]","author":"Zhu","year":"2022"},{"key":"B32","first-page":"326","article-title":"Literature analysis of severe skin adverse event induced by immune checkpoint inhibitors","volume":"19","author":"Zihang","year":"2022","journal-title":"Chin. J. Drug Appl. Monit."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1684390\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T06:29:20Z","timestamp":1767335360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1684390\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":32,"alternative-id":["10.3389\/fphar.2025.1684390"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1684390","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"article-number":"1684390"}}